[go: up one dir, main page]

AR103316A1 - VIRAL TERMINASE DIHYDROQUINAZOLINE INHIBITORS - Google Patents

VIRAL TERMINASE DIHYDROQUINAZOLINE INHIBITORS

Info

Publication number
AR103316A1
AR103316A1 ARP150104334A ARP150104334A AR103316A1 AR 103316 A1 AR103316 A1 AR 103316A1 AR P150104334 A ARP150104334 A AR P150104334A AR P150104334 A ARP150104334 A AR P150104334A AR 103316 A1 AR103316 A1 AR 103316A1
Authority
AR
Argentina
Prior art keywords
dihydroquinazoline
inhibitors
deuterium
viral
terminase
Prior art date
Application number
ARP150104334A
Other languages
Spanish (es)
Original Assignee
Auspex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auspex Pharmaceuticals Inc filed Critical Auspex Pharmaceuticals Inc
Publication of AR103316A1 publication Critical patent/AR103316A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/84Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente solicitud se refiere a moduladores de dihidroquinazolina de una infección viral, composiciones farmacéuticas de los mismos y métodos de uso de los mismos. Reivindicación 1: Un compuesto caracterizado por la fórmula estructural (1) o una sal del mismo, en donde: R¹ y R² se seleccionan independientemente del grupo que consiste en -CH₃, -CH₂D, -CD₂H y -CD₃; R³ - R²⁵ se seleccionan independientemente del grupo que consiste en hidrógeno y deuterio; y al menos uno de R¹ - R²⁵ es deuterio o contiene deuterio.The present application relates to dihydroquinazoline modulators of a viral infection, pharmaceutical compositions thereof and methods of use thereof. Claim 1: A compound characterized by the structural formula (1) or a salt thereof, wherein: R¹ and R² are independently selected from the group consisting of -CH₃, -CH₂D, -CD₂H and -CD₃; R³ - R²⁵ are independently selected from the group consisting of hydrogen and deuterium; and at least one of R¹ - R²⁵ is deuterium or contains deuterium.

ARP150104334A 2014-12-29 2015-12-29 VIRAL TERMINASE DIHYDROQUINAZOLINE INHIBITORS AR103316A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462097443P 2014-12-29 2014-12-29

Publications (1)

Publication Number Publication Date
AR103316A1 true AR103316A1 (en) 2017-05-03

Family

ID=56284952

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150104334A AR103316A1 (en) 2014-12-29 2015-12-29 VIRAL TERMINASE DIHYDROQUINAZOLINE INHIBITORS

Country Status (3)

Country Link
AR (1) AR103316A1 (en)
TW (1) TW201629043A (en)
WO (1) WO2016109360A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10851112B2 (en) 2016-08-08 2020-12-01 Medshine Discovery Inc. Anti-HCMV virus compound
AU2019218150B2 (en) * 2018-02-08 2021-05-13 Phaeno Therapeutics Co., Ltd. Crystal form of 3,4-dihydrothieno[3,2-d]pyrimidine compound and preparation method therefor
CN115322157B (en) * 2022-06-02 2023-12-05 浙江车头制药股份有限公司 Letermopevir intermediate compound, preparation method and application thereof
CN117229223A (en) * 2022-06-08 2023-12-15 苏州远智医药科技有限公司 Heterocyclic derivative and pharmaceutical composition and application thereof
CN117486808A (en) * 2023-11-06 2024-02-02 北京康立生医药技术开发有限公司 A new preparation method for key intermediates of letermovir
CN117658928A (en) * 2023-11-07 2024-03-08 北京康立生医药技术开发有限公司 A new preparation method of drug intermediates for preventing CMV infection

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005027517A1 (en) * 2005-06-15 2006-12-21 Bayer Healthcare Ag Process for the preparation of dihydroquinazolines
CA2768043A1 (en) * 2009-07-27 2011-02-10 Auspex Pharmaceuticals, Inc. Cyclopropyl modulators of p2y12 receptor
DE102012101659A1 (en) * 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salts of a dihydroquinazoline derivative
JP2015531776A (en) * 2012-09-04 2015-11-05 セルジーン コーポレイション Isotopologue of 3- (5-amino-2-methyl-4-oxoquinazolin-3 (4H) -yl) piperidine-2,6-dione and process for producing the same

Also Published As

Publication number Publication date
TW201629043A (en) 2016-08-16
WO2016109360A1 (en) 2016-07-07

Similar Documents

Publication Publication Date Title
AR103316A1 (en) VIRAL TERMINASE DIHYDROQUINAZOLINE INHIBITORS
CL2015003615A1 (en) Substituted nucleosides, nucleotides and analogs thereof.
CO2018004124A2 (en) Heterocyclic compounds
MX2017006266A (en) HETEROARILO COMPOUNDS AS INHIBITORS OF KINASES ASSOCIATED WITH THE INTERLEUCINE 1 (IRAK) RECEIVER AND ITS USES.
MX2016003199A (en) AZAPIRIDONE COMPOUNDS AND USES OF THE SAME.
EA201591455A1 (en) DERIVATIVES OF BENZIMIDAZOLONE AS A BROMODOMENE INHIBITORS
BR112017006253A2 (en) new compounds
CR20150454A (en) AMIDA COMPOUNDS FOR HIV TREATMENT
EA201492214A1 (en) HEPATITIS C VIRUS INHIBITORS
BR112017000246A2 (en) compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound or salt
AR094812A1 (en) DERIVED FROM MONOCYCLIC PYRIDINE AS AN FGFR INHIBITOR
BR112016014020A8 (en) tetrahydropyridopyrazines modulators of gpr6.
AR097082A1 (en) THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE
AR104174A1 (en) OXADIAZOLS REPLACED WITH DEUTERIO
EA201790571A1 (en) PYRROPHYRIMIDINES FOR APPLICATION IN INFECTION CAUSED BY THE FLU VIRUS
BR112017006240A2 (en) new compounds
AR103355A1 (en) MODULATORS OF CYCLOPROPANOCARBOXAMIDE OF THE TRANSMEMBRANE CHEMICAL FIBROSIS DRIVING REGULATOR
BR112015018509A2 (en) imidazo pyridine compounds
EA201592184A1 (en) 4'-FLUOR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES
NZ709986A (en) Pharmaceutical compositions comprising nitroxyl donors
BR112015016325A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND USES OF A COMPOSITION, COMPOUND, PRO-DRUG, OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
CO2018010787A2 (en) Griseofulvin compound
AR103317A1 (en) MELATONINE RECEPTORS DIHYDROBENZOFURAN CYCLOPROPIL MODULATORS
BR112017018305A2 (en) deacetoxytubulisine h and analogs thereof
MX2018009459A (en) Sulfonamide derivative and pharmaceutical composition containing same.

Legal Events

Date Code Title Description
FB Suspension of granting procedure